Simtuzumab    (DrugBank: Simtuzumab)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
85特発性間質性肺炎9
94原発性硬化性胆管炎2

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 514 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-001571-36-PL09/09/201317/06/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER Idiopathic pulmonary fibrosis
MedDRA version: 18.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2United States;Czech Republic;Canada;Spain;Belgium;Poland;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of
2EUCTR2012-001571-36-DE17/06/201302/04/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER). - RAINIER Idiopathic pulmonary fibrosis
MedDRA version: 18.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of
3EUCTR2012-001571-36-BE28/05/201326/03/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER Idiopathic pulmonary fibrosis
MedDRA version: 18.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2Korea, Democratic People's Republic of;Israel;United Kingdom;Switzerland;Italy;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany;Korea, Republic of;United States;Spain
4EUCTR2012-001571-36-ES12/05/201316/05/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINER Idiopathic pulmonary fibrosis
MedDRA version: 16.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2United States;Czech Republic;Canada;Poland;Belgium;Spain;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of
5EUCTR2012-001571-36-CZ29/04/201315/04/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER). - RAINIER Idiopathic pulmonary fibrosis
MedDRA version: 18.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2012-001571-36-IT26/04/201328/02/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER Idiopathic pulmonary fibrosis
MedDRA version: 14.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of
7EUCTR2012-001571-36-GB19/04/201328/03/2013A study to evaluate if a new drug is effective in preventing the progression of lung fibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER Idiopathic pulmonary fibrosis
MedDRA version: 17.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: GS-6624
INN or Proposed INN: Simtuzumab
Other descriptive name: GS-6624
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 2United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;Italy;United Kingdom;Korea, Republic of
8NCT01769196January 31, 201314/1/2013Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Simtuzumab;Drug: Simtuzumab placeboGilead SciencesNULLTerminated45 Years85 YearsAll544Phase 2United States;Australia;Belgium;Canada;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;Czech Republic
9NCT01759511October 18, 201215/11/2012Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: SimtuzumabGilead SciencesNULLTerminated18 YearsN/AAll34Phase 2United States

94. 原発性硬化性胆管炎 [臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 134 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-002473-61-IT18/06/201304/04/2013An investigational study to assess the safety and efficacy of a new investigational drug in subjects with primary sclerosing cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) Primary Sclerosing Cholangitis (PSC)
MedDRA version: 14.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: Simtuzumab
Product Code: GS-6624
INN or Proposed INN: Simtuzimab
Product Name: Simtuzimab
Product Code: GS-6624
INN or Proposed INN: Simtuzimab
Gilead Sciences IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
225Phase 2United States;Canada;Denmark;United Kingdom;Italy;Sweden
2NCT01672853March 4, 201322/8/2012Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis (PSC)Biological: Simtuzumab;Biological: PlaceboGilead SciencesNULLCompleted18 Years70 YearsAll235Phase 2United States;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom